Occlusive implant compositions
Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.
1. A composition comprising:
one or more species in solvent;
wherein the one or more species are capable of crosslinking to form an implantable network;
wherein the implantable network has a (i) storage modulus G′ ranging from 0.001 Pa to 10,000 Pa and a (ii) a loss modulus G″ ranging from 0.1 Pa to 1,000 Pa, at a temperature of from 20-160° C.;
wherein the one or more species and/or the implantable network are capable of being injected into a bodily lumen; and
wherein the implantable network is capable of inducing azoospermia in vivo.
2. The composition of claim 1 , wherein one or more of the species comprises one or more of natural or synthetic monomers, polymers, copolymers or block copolymers, biocompatible monomers, polymers, copolymers or block copolymers, polystyrene, neoprene, polyetherether ketone (PEEK), carbon reinforced PEEK, polyphenylene, polyetherketoneketone (PEKK), polyaryletherketone (PAEK), polyphenylsulphone, polysulphone, polyurethane, polyethylene, low-density polyethylene (LDPE), linear low-density polyethylene (LLDPE), high-density polyethylene (HDPE), polypropylene, polyetherketoneetherketoneketone (PEKEKK), nylon, fluoropolymers, polytetrafluoroethylene (PTFE), TFE (tetrafluoroethylene), polyethylene terephthalate (PET or PETE), FEP (fluorinated ethylene propylene), PFA (perfluoroalkoxy alkane), and/or polymethylpentene (PMP) styrene maleic anhydride, styrene maleic acid (SMA), polyurethane, silicone, polymethyl methacrylate, polyacrylonitrile, poly (carbonate-urethane), poly (vinyl acetate), nitrocellulose, cellulose acetate, urethane, urethane/carbonate, polylactic acid, polyacrylamide (PAAM), poly (N-isopropylacrylamine) (PNIPAM), poly (vinylmethylether), poly (ethylene oxide), poly (ethyl (hydroxyethyl) cellulose), poly(2-ethyl oxazoline), polylactide (PLA), polyglycolide (PGA), poly(lactide-co-glycolide) PLGA, poly(e-caprolactone), polydiaoxanone, polyanhydride, trimethylene carbonate, poly(β-hydroxybutyrate), poly(g-ethyl glutamate), poly(DTH-iminocarbonate), poly(bisphenol A iminocarbonate), poly(orthoester) (POE), polycyanoacrylate (PCA), polyphosphazene, polyethyleneoxide (PEO), polyethyleneglycol (PEG), polyacrylacid (PAA), polyacrylonitrile (PAN), polyvinylacrylate (PVA), polyvinylpyrrolidone (PVP), polyglycolic lactic acid (PGLA), poly(2-hydroxypropyl methacrylamide) (pHPMAm), poly(vinyl alcohol) (PVOH), PEG diacrylate (PEGDA), poly(hydroxyethyl methacrylate) (pHEMA), N-isopropylacrylamide (NIPA), poly(vinyl alcohol) poly(acrylic acid) (PVOH-PAA), collagen, silk, gelatin, hyaluron, cellulose, chitin, dextran, casein, albumin, ovalbumin, heparin sulfate, starch, agar, heparin, alginate, fibronectin, fibrin, keratin, pectin, elastin, ethylene vinyl acetate, ethylene vinyl alcohol (EVOH), polyethylene oxide, PLA or PLLA (poly(L-lactide) or pol(L-lactic acid)), poly(D,L-lactic acid), poly(D,L-lactide), polydimethylsiloxane or dimethicone (PDMS), poly(isopropyl acrylate) (PIPA), polyethylene vinyl acetate (PEVA), PEG styrene, polytetraflurorethylene RFE, fluorinated polyethylene (FLPE), RFE PFPE (perfluoropolyether), methyl palmitate, temperature responsive polymers, poly(N-isopropylacrylamide) (NIPA), polycarbonate, polyethersulfone, polycaprolactone, polymethyl methacrylate, polyisobutylene, nitrocellulose, medical grade silicone, cellulose acetate, cellulose acetate butyrate, polyacrylonitrile, poly(lactide-co-caprolactone (PLCL), and/or chitosan.
3. The composition of claim 1 , wherein the solvent comprises an aqueous solvent, organic solvent, or a combination of both aqueous and organic solvents.
4. The composition of claim 1 , wherein the solvent comprises one or more of dimethyl sulfoxide (DMSO), sodium bicarbonate, potassium bicarbonate, chloroform, or alkaline solutions.
5. The composition of claim 1 , wherein one or more of the species is a polymer with a weight average molecular weight (M w ) or number-average molecular weight (M n ) ranging from about 1,000 to 1,000,000 Daltons.
6. The composition of claim 1 having a viscosity of 1-7 Pa*s.
7. The composition of claim 1 having a pH in the range of 8 to 9.
8. The composition of claim 1 having an alkaline pH.
9. The composition of claim 1 having a pH in the range of neutral to acidic.
10. The composition of claim 1 , wherein the composition has a mass percent swelling in the range of 40-120%.
11. The composition of claim 1 , wherein one or more of the species comprises microbubbles with diameters ranging from about 1 μm to 10 μm.
12. The composition of claim 1 , wherein the solvent is aqueous.
13. The composition of claim 1 , wherein the implantable network has a selected length, width or diameter within the bodily lumen based on lumen diameter, injection volume of the composition and a coefficient (Beta).